Protein Summary
Integrin alpha-2/beta-1 is a receptor for laminin, collagen, collagen C-propeptides, fibronectin and E-cadherin. It recognizes the proline-hydroxylated sequence G-F-P-G-E-R in collagen. It is responsible for adhesion of platelets and other cells to collagens, modulation of collagen and collagenase gene expression, force generation and organization of newly synthesized extracellular matrix. (Microbial infection) Integrin ITGA2:ITGB1 acts as a receptor for Human rotavirus A. (Microbial infection) Integrin ITGA2:ITGB1 acts as a receptor for Human echoviruses 1 and 8. This gene encodes the alpha subunit of a transmembrane receptor for collagens and related proteins. The encoded protein forms a heterodimer with a beta subunit and mediates the adhesion of platelets and other cell types to the extracellular matrix. Loss of the encoded protein is associated with bleeding disorder platelet-type 9. Antibodies against this protein are found in several immune disorders, including neonatal alloimmu ...more
- ENST00000296585
- ENSP00000296585
- ENSG00000164171
- CD49B
- BR
- GPIa
- CD49B
- HPA-5
- VLA-2
- VLAA2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
biological process | 0.99 | ||
biological term | 0.99 | ||
gene perturbation | 0.95 | ||
molecular function | 0.86 | ||
protein domain | 0.85 | ||
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 437.81 (req: < 5)
Gene RIFs: 232 (req: <= 3)
Antibodies: 1284 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 437.81 (req: >= 5)
Gene RIFs: 232 (req: > 3)
Antibodies: 1284 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 55
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0
Protein Data Bank (7)
1 – 5 of 7
PDB Structure Id | Ligand | Method | Resolution (Ã…) | M.W. (kDa) | Pub Year | Title |
---|
PDB Structure Id | M.W. | Resolution | Pub Year |
---|
Pathways (259)
Reactome (17)
KEGG (14)
PathwayCommons (8)
WikiPathways (220)
Click on a row in the table to change the structure displayed.
Items per page:
1 – 5 of 17
Data Source | Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|---|
Reactome | Axon guidance | ||||
Reactome | CHL1 interactions | ||||
Reactome | Developmental Biology | ||||
Reactome | ECM proteoglycans | ||||
Reactome | Extracellular matrix organization | ||||
Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|
Axon guidance | ||||
CHL1 interactions | ||||
Developmental Biology | ||||
ECM proteoglycans | ||||
Extracellular matrix organization | ||||
Gene Ontology Terms (65)
Functions (11)
Components (10)
Processes (44)
Items per page:
10
1 – 10 of 11
GO Term | Evidence | Assigned by | ||
---|---|---|---|---|
Inferred from Physical Interaction (IPI) | UniProtKB | |||
Inferred from Mutant Phenotype (IMP) | UniProtKB | |||
Inferred from Mutant Phenotype (IMP) | UniProtKB | |||
Inferred from Mutant Phenotype (IMP) | UniProtKB | |||
Inferred from Sequence or structural Similarity (ISS) | ARUK-UCL | |||
Traceable Author Statement (TAS) | ARUK-UCL | |||
Inferred from Electronic Annotation (IEA) | Ensembl | |||
Inferred from Electronic Annotation (IEA) | Ensembl | |||
Inferred from Electronic Annotation (IEA) | UniProtKB-KW | |||
Inferred from Electronic Annotation (IEA) | Ensembl | |||
Protein-Protein Interactions (236)
1 – 10 of 236
LGALS8
Novelty: 0.00746585
p_int: 0.999999167
p_ni: 8.32e-7
Data Source: BioPlex
BTNL8
Novelty: 0.35087719
p_int: 0.999993751
p_ni: 0.000006249
Data Source: BioPlex
MGAT4C
Family: Enzyme
Novelty: 0.0221593
p_int: 0.997838237
p_ni: 0.00216161
p_wrong: 1.53e-7
Data Source: BioPlex
EDDM3B
Novelty: 0.07909894
p_int: 0.996628845
p_ni: 0.003298579
p_wrong: 0.000072576
Data Source: BioPlex
LGALS3
Novelty: 0.00032884
p_int: 0.994410203
p_ni: 0.005582239
p_wrong: 0.000007558
Score: 0.259
Data Source: BioPlex,STRINGDB
TMED6
Novelty: 0.61538462
p_int: 0.992596317
p_ni: 0.007268902
p_wrong: 0.000134782
Data Source: BioPlex
SCGB1D1
Novelty: 0.00676385
p_int: 0.989638536
p_ni: 0.01030757
p_wrong: 0.000053895
Data Source: BioPlex
ADAM18
Family: Enzyme
Novelty: 0.24489796
p_int: 0.96693406
p_ni: 0.033044539
p_wrong: 0.0000214
Data Source: BioPlex
CD160
Novelty: 0.02046796
p_int: 0.959889276
p_ni: 0.040103897
p_wrong: 0.000006827
Data Source: BioPlex
SERPINA12
Novelty: 0.00636095
p_int: 0.959160053
p_ni: 0.036830624
p_wrong: 0.004009323
Data Source: BioPlex
Publication Statistics
PubMed Score 437.81
PubMed score by year
PubTator Score 312.5
PubTator score by year
Amino Acid Sequence
Residue Counts
Sequence
MGPERTGAAPLPLLLVLALSQGILNCCLAYNVGLPEAKIFSGPSSEQFGYAVQQFINPKGNWLLVGSPWS
1-70
GFPENRMGDVYKCPVDLSTATCEKLNLQTSTSIPNVTEMKTNMSLGLILTRNMGTGGFLTCGPLWAQQCG
70-140
NQYYTTGVCSDISPDFQLSASFSPATQPCPSLIDVVVVCDESNSIYPWDAVKNFLEKFVQGLDIGPTKTQ
140-210
VGLIQYANNPRVVFNLNTYKTKEEMIVATSQTSQYGGDLTNTFGAIQYARKYAYSAASGGRRSATKVMVV
210-280
VTDGESHDGSMLKAVIDQCNHDNILRFGIAVLGYLNRNALDTKNLIKEIKAIASIPTERYFFNVSDEAAL
280-350
LEKAGTLGEQIFSIEGTVQGGDNFQMEMSQVGFSADYSSQNDILMLGAVGAFGWSGTIVQKTSHGHLIFP
350-420
KQAFDQILQDRNHSSYLGYSVAAISTGESTHFVAGAPRANYTGQIVLYSVNENGNITVIQAHRGDQIGSY
420-490
FGSVLCSVDVDKDTITDVLLVGAPMYMSDLKKEEGRVYLFTIKKGILGQHQFLEGPEGIENTRFGSAIAA
490-560
LSDINMDGFNDVIVGSPLENQNSGAVYIYNGHQGTIRTKYSQKILGSDGAFRSHLQYFGRSLDGYGDLNG
560-630
DSITDVSIGAFGQVVQLWSQSIADVAIEASFTPEKITLVNKNAQIILKLCFSAKFRPTKQNNQVAIVYNI
630-700
TLDADGFSSRVTSRGLFKENNERCLQKNMVVNQAQSCPEHIIYIQEPSDVVNSLDLRVDISLENPGTSPA
700-770
LEAYSETAKVFSIPFHKDCGEDGLCISDLVLDVRQIPAAQEQPFIVSNQNKRLTFSVTLKNKRESAYNTG
770-840
IVVDFSENLFFASFSLPVDGTEVTCQVAASQKSVACDVGYPALKREQQVTFTINFDFNLQNLQNQASLSF
840-910
QALSESQEENKADNLVNLKIPLLYDAEIHLTRSTNINFYEISSDGNVPSIVHSFEDVGPKFIFSLKVTTG
910-980
SVPVSMATVIIHIPQYTKEKNPLMYLTGVQTDKAGDISCNADINPLKIGQTSSSVSFKSENFRHTKELNC
980-1050
RTASCSNVTCWLKDVHMKGEYFVNVTTRIWNGTFASSTFQTVQLTAAAEINTYNPEIYVIEDNTVTIPLM
1050-1120
IMKPDEKAEVPTGVIIGSIIAGILLLLALVAILWKLGFFKRKYEKMTKNPDEIDETTELSS
1120-1181
MGPERTGAAPLPLLLVLALSQGILNCCLAYNVGLPEAKIFSGPSSEQFGYAVQQFINPKGNWLLVGSPWSGFPENRMGDVYKCPVDLSTATCEKLNLQTSTSIPNVTEMKTNMSLGLILTRNMGTGGFLTCGPLWAQQCGNQYYTTGVCSDISPDFQLSASFSPATQPCPSLIDVVVVCDESNSIYPWDAVKNFLEKFVQGLDIGPTKTQVGLIQYANNPRVVFNLNTYKTKEEMIVATSQTSQYGGDLTNTFGAIQYARKYAYSAASGGRRSATKVMVVVTDGESHDGSMLKAVIDQCNHDNILRFGIAVLGYLNRNALDTKNLIKEIKAIASIPTERYFFNVSDEAALLEKAGTLGEQIFSIEGTVQGGDNFQMEMSQVGFSADYSSQNDILMLGAVGAFGWSGTIVQKTSHGHLIFPKQAFDQILQDRNHSSYLGYSVAAISTGESTHFVAGAPRANYTGQIVLYSVNENGNITVIQAHRGDQIGSYFGSVLCSVDVDKDTITDVLLVGAPMYMSDLKKEEGRVYLFTIKKGILGQHQFLEGPEGIENTRFGSAIAALSDINMDGFNDVIVGSPLENQNSGAVYIYNGHQGTIRTKYSQKILGSDGAFRSHLQYFGRSLDGYGDLNGDSITDVSIGAFGQVVQLWSQSIADVAIEASFTPEKITLVNKNAQIILKLCFSAKFRPTKQNNQVAIVYNITLDADGFSSRVTSRGLFKENNERCLQKNMVVNQAQSCPEHIIYIQEPSDVVNSLDLRVDISLENPGTSPALEAYSETAKVFSIPFHKDCGEDGLCISDLVLDVRQIPAAQEQPFIVSNQNKRLTFSVTLKNKRESAYNTGIVVDFSENLFFASFSLPVDGTEVTCQVAASQKSVACDVGYPALKREQQVTFTINFDFNLQNLQNQASLSFQALSESQEENKADNLVNLKIPLLYDAEIHLTRSTNINFYEISSDGNVPSIVHSFEDVGPKFIFSLKVTTGSVPVSMATVIIHIPQYTKEKNPLMYLTGVQTDKAGDISCNADINPLKIGQTSSSVSFKSENFRHTKELNCRTASCSNVTCWLKDVHMKGEYFVNVTTRIWNGTFASSTFQTVQLTAAAEINTYNPEIYVIEDNTVTIPLMIMKPDEKAEVPTGVIIGSIIAGILLLLALVAILWKLGFFKRKYEKMTKNPDEIDETTELSS
Find similar targets by: